Our Resource Meetups are free online gatherings for people affected by colorectal cancer seeking access to resources and peer-to-peer support.
Our Clinical Trial Finder is a one-stop place to find and learn more about high-impact research studies for CRC patients. The current data are limited to MSS (microsatellite-stable) and stage IV CRC patients.
Our Path to a Cure report is our plan for the future. This plan is not just for Fight CRC, but for everyone who is willing to champion this cause.
Shop our online store to raise awareness everywhere you go! From t-shirts and fanny packs to patient education resources, we have a little bit of everything.
Raise Awareness. Be an Advocate. Host an Event.
Program Status Clinical trial’s patient recruitment status
Phase Phase of the clinical trial that is recruiting (I, II, or III)
Immunotherapy-centered Trial A flag to indicate whether the trial is an immunotherapy trial
Prior Immunotherapy Allowed Whether the clinical trial is open to patients who have received prior immunotherapy
CRC-directed Trial A flag to indicate whether the trial is specifically targeting colon cancer, rectal cancer, or colorectal cancer patients
Drugs Therapeutics used in the clinical trial
Tags
Inclusion Criteria
Selected Inclusion Criteria:
Age ≥ 18 years of age at the time of signing the informed consent. Patients > 70 years of age must have a G8 Health State Screening Tool (geriatric screening tool) score >. Proficient mismatch repair/microsatellite stable (pMMR/MSS), histologically or cytologically-confirmed adenocarcinoma of the colon or rectum. Patients with any BRAF or KRAS mutation status are eligible. Unresectable and measurable or evaluable disease per RECIST v1.1 ECOG performance status of 0 to 1 A formalin-fixed paraffin-embedded (FFPE) tumor specimen (from archival or fresh biopsy) with an associated pathology report documenting pMMR/MSS mCRC must be confirmed to be available to send to the Sponsor for planned retrospective biomarker analyses. Adequate organ function
Selected
Exclusion Criteria
Exclusion Criteria:
Prior systemic therapy for mCRC. Patients who received adjuvant/neoadjuvant therapy (ie, treatment with curative intent) for colorectal cancer are eligible if it has been ≥ 6 months between the last dose of systemic chemotherapy and the date of informed consent. Any radiotherapy, chemotherapy, immunotherapy, biologic, investigational, or hormonal therapy for cancer treatment (except for adjuvant hormonal therapy for breast cancer or prostate cancer defined as M0 disease or PSA persistence/recurrence without metastatic disease) within 3 weeks prior to the first dose of trilaciclib/placebo. Receipt of any low-dose systemic chemotherapeutic agent (e.g., low-dose methotrexate for rheumatoid arthritis) administered for a nononcologic purpose within 3 weeks prior to the first dose of trilaciclib/placebo. Presence of central nervous system (CNS) metastases/leptomeningeal disease requiring immediate treatment with radiation therapy or steroids QTcF interval > 450 msec (males) or > 470 msec (females) at screening. For patients with ventricular pacemakers, QTcF > 500 msec. Personal or family history of long QT syndrome Symptomatic peripheral neuropathy History of interstitial lung disease (ILD) Prior allogeneic or autologous hematopoietic stem cell or bone marrow transplantation
NCT ID Trial ID number from clinicaltrials.gov or other database
Date Trial Added Date on which the clinical trial was added to the clinicaltrials.gov website
Updated Date Date on which the clinical trial was updated on the clinicaltrials.gov website